Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

US weight loss centre starts using Tethys' diabetes risk score

This article was originally published in Clinica

  • News

Executive Summary

Structure House, a weight loss centre in Durham, North Carolina, has initiated a study using Tethys Bioscience's PreDx Diabetes Risk Score (DRS) on 50 participants in its 28-day programme. PreDx DRS is a blood test that measures a person's risk of developing diabetes within five years. Emeryville, California-based Tethys hopes that it will help doctors target preventative strategies, such as weight loss programmes, to the most at-risk individuals. The study will use PreDx DRS to assess whether Structure House's intensive lifestyle change programme can alter patients' probability of developing diabetes. It will also evaluate whether more specific feedback on diabetes risk at the start of the regimen will increase the subjects' motivation to change their lifestyle.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT044083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By